SCHEMBL2410667

SCHEMBL2410667

CC(C)(Sc1nc(CCOc2cccc(-c3ccc(F)cc3)c2)cs1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.41
TP53 P04637 1/20 0.41
PPARA Q07869 2/20 0.40
SLC13A5 Q86YT5 2/20 0.39
RAB9A P51151 2/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
GAA P10253 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PPARD Q03181 1/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
FFAR4 Q5NUL3 2/20 0.37
FFAR1 O14842 1/20 0.37
SLC22A12 Q96S37 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2408505 0.93 TP53 (0.45) TP53PPARARAB9ASMN1; SMN2KDM4E
SCHEMBL2417561 0.91 MRGPRX4 (0.49) MRGPRX4PPARARAB9AGAASMN1; SMN2
SCHEMBL2398837 0.90 RAB9A (0.49) TP53PPARARAB9ASMN1; SMN2NPC1
SCHEMBL2412207 0.89 SLC13A5 (0.42) TP53PPARASLC13A5HDAC1HDAC2
SCHEMBL2415153 0.87 PPARA (0.45) PPARARAB9ASMN1; SMN2NPC1PPARD
SCHEMBL2412948 0.87 PPARA (0.42) PPARASLC13A5ALDH1A1KDM4EPPARD
SCHEMBL2415214 0.86 KDM4E (0.40) TP53PPARASMN1; SMN2KDM4EPPARD
SCHEMBL2413931 0.86 RAB9A (0.38) TP53PPARARAB9ASMN1; SMN2NPC1
SCHEMBL2413830 0.85 RAB9A (0.53) PPARARAB9ASMN1; SMN2PPARD
SCHEMBL2412449 0.85 RAB9A (0.38) TP53PPARARAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG MRGPRX4 1764/4885TP53 2553/4885PPARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.